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2. Abstract 
The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise 
diverse entities of hematopoetic stem cell disorders with hematopoetic stem cell 
transplantation as the only curative therapeutic option. A collective finding of some 
subgroups is the activating point mutation of JAK2 p.V617F, important for diagnosis and 
detection of minimal residual disease (MRD) but a rather late event in the course of MPN. 
In this study, we first focused on characteristics of the neoplastic peripheral blood CD34- 
positive stem cell fraction. Thus, we could reveal a characteristic aberrant morphology and 
phenotype, and performing cDNA- array analysis most notably an imbalance of DNA- 
dependent protein kinase subunits which may contribute  to the accumulation of chromosomal 
aberrations, accumulation of hematopoetic cell, and prolongation of CD34- positive 
peripheral blood stem cells life span (Wickenhauser, Perez, et al. 2003; Siebolts, Breuhahn, et 
al. 2009). Moreover, there is evidence of a distinct, non-neoplastic, CD34- positive peripheral 
blood stem cell population which may offer perspectives in treatment of the diseases 
(Siebolts, Ates, et al. 2005). 
The CD34- positive stem cell fraction, as the underlying source of the malignancy, is of 
course of particular importance, not only for understanding of the pathophysiological process 
but also for understanding of relapse and regenerative incidents. Performing fluorescence in 
situ hybridization on bone marrow biopsies, we found an almost complete chimerism 
following stem cell transplantation concerning the differentiated hematopoesis, whereas 
CD34- positive cells remained of recipient origin to a higher proportion (Thiele, Varus, et al. 
2007; Siebolts, Thiele, et al. 2008). 
Since hematopoetic stem cell transplantation, especially after invention of reduced intensity 
conditioning (RIC) is a feasible curative option for an increasing number of MPN patients, 
reliable detection of the specific JAK2 p.V617F mutation as a sign of minimal residual 
disease (MRD) becomes more and more important. Therefore, we created in combination of a 
robust QPCR with a wild- type blocking PCR, a powerful tool for reliable detection of MRD 
in these patients (Siebolts, Lange, et al. 2010). 
Future prospects of MPN research will also focus on the newly-discovered field of non-
coding RNA. Therefore, we tested the possibility to perform further retrospective analysis on 
easily accessible paraffin embedded formalin fixed tissue, and could show for the first time 
that extraction of sufficient amount of miRNA, with subsequent expression analysis is 
possible even after decalcification and also after decades (Siebolts, Varnholt, et al. 2009).
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2. Zusammenfassung 
Die Transplantation hematopoetischer Stammzellen gilt zurzeit als die einzige kurative 
Therapie der Philadelphia Chromosom negativen myeloproliferativen Neoplasien und die 
Kontrolle der minimalen Resterkrankung ist somit von besonderem Interesse. Die in viele 
Fällen nachweisbare aktivierende Punktmutation JAK2 p.V617F stellt wahrscheinlich nur ein 
Epiphänomen der Erkrankungen dar, ist aber für die Diagnostik und Nachweis einer 
minimalen Resterkrankung von besonderer Bedeutung. 
Die vorliegende Arbeit zeigte in ersten Untersuchungen einen charakteristischen aberranten 
Phänotyp der neoplastischen CD34- positiven Stammzellen des peripheren Blutes, zusammen 
mit einer Unausgewogenheit der verschiedenen Untereinheiten der DNA- abhängigen 
Proteinkinase. Dies könnte ursächlich zu verschiedenen bekannten Veränderungen im 
Rahmen der Erkrankung beitragen wie z.B. Anreicherung von genetischen Störungen, 
Vermehrung der peripheren Blutzellen sowie die Verlängerung der Lebenspanne CD34- 
positiver hämatopoetischer Stammzellen (Wickenhauser, Perez, et al. 2003; Siebolts, 
Breuhahn, et al. 2009). Zudem ergeben sich Hinweise auf eine persistierende nicht 
neoplastische CD34- positive hämatopoetische Stammzellpopulation im peripheren Blut, die 
zukünftig im Sinne einer Reservepopulation therapeutische Optionen bieten könnte (Siebolts, 
Ates, et al. 2005). 
Weitere Untersuchungen mittels Fluoreszenz in situ Hybridisierung an Knochenmarkbiopsien 
zeigten, dass nach Stammzelltransplantation ein nahezu vollständiger Spenderchimärismus, 
vor allem der ausdifferenzierten hämatopoetischen Zellen bei Patienten mit unkompliziertem 
Verlauf schon früh erreicht wird, jedoch eine signifikante CD34- positive hämatopoetische 
Stammzellpopulation als mögliches Reservoir für zukünftige Rezidive verbleibt. (Thiele, 
Varus, et al. 2007; Siebolts, Thiele, et al. 2008). 
Im Rahmen der Stammzelltransplantation JAK2 p.V617F positiver myeloproliferativer 
Neoplasien ist eine personalisierte Kontrolle der minimalen Resterkrankung auf molekularer 
Ebene durch Anwendung moderner, hochsensitiver Methoden möglich geworden. In weiteren 
Studien im Rahmen dieser Arbeit gelang uns die Entwicklung einer robusten und 
hochsensitiven allelspezifischen quantitativen PCR durch die innovative Reduktion des 
überwiegenden Anteils kompetitiver Wildtyp DNA (Siebolts, Lange, et al. 2010). 
Das neu entdeckte Gebiet der nicht kodierenden RNA eröffnet neue Ansätze zur Diagnostik 
und Therapie möglicherweise auch der myeloproliferativen Neoplasien. Vor diesem 
Hintergrund konnten wir zeigen, dass die Möglichkeit besteht, aus archiviertem, 
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formalinfixierten, teils dekalzifizierten und paraffineingebetteten Material auch nach 
Jahrzehnten ausreichend Material für vergleichende Expressionsanalysen zu gewinnen 
(Siebolts, Varnholt, et al. 2009).  
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3. Introduction 
This document presents different aspects of the classic myeloproliferative neoplasms (MPN) 
and in particular about polycythemia vera (PV) and primary myelofibrosis (PMF). Primarily, 
questions concerning pathophysiology and diagnostic approaches of the classic Ph- MPN 
were in the spotlight. The following chapter gives a short synopsis about the actual relevant 
knowledge of pathophysiology, the new field of targeted therapy and molecular diagnostics in 
MPN. 
 
3.1 Myeloproliferative neoplasms 
 
William Damashek was the first to describe the concept of myeloproliferative disorders in 
1951, where the classic myeloproliferative disease (chronic myelogenous leukemia (CML), 
polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) 
were defined (Dameshek 1951).  
In 2001, the World Health Organization (WHO) committee for the classification of myeloid 
neoplasms, inaugurated the term chronic myeloproliferative diseases (CMPD) which covers 
additionally the entities of chronic neutrophilic leukemia (CNL), chronic eosinophilic 
leukemia/ hypereosinophilic syndrome (CEL/HES) and CMPD, unclassifiable, among with 
the classic MPD (Jaffe ES 2001; Vardiman JW 2001). In the broader context the CMPDs 
were considered as one of four major categories of chronic myeloid neoplasms, the other three 
being myelodysplastic syndromes (MDS), MDS/MPD and mast cell diseases (MCD) (Jaffe 
ES 2001). 
The revised 2008 WHO classification system changed the term disease into neoplasm because 
of the meanwhile accepted clonal origin of these entities. Now these diseases are subdivided 
in the category of MPN, which was formerly known as CMPD, and MDS/MPN for 
MDS/MPD. In addition, the MPN category now includes mast cell diseases whereas the 
previous CMPD subcategory of CEL/HES is now re-organized into HES, CEL not otherwise 
categorized (CEL-NOC) and myeloid neoplasms associated with eosinophilia and 
abnormalities of PDGFRA, PDGFRB and FGFR1 (Table 1). The latter group is now assigned 
a new category of its own, whereas both HES and CEL-NOC remain subcategories of MPNs 
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(Table 1) (Vardiman JW 2001; Swerdlow SH 2008; Tefferi and Vardiman 2008; Vardiman, 
Thiele, et al. 2009).  
 
1. Acute myeloid leukemia 
2. Myelodysplastic syndromes (MDS) 
3. Myeloproliferative neoplasms (MPN)  
 3.1 Chronic myelogenous leukemia  
 3.2 Polycythemia vera  
 3.3 Essential thrombocythemia  
 3.4 Primary myelofibrosis  
 3.5 Chronic neutrophilic leukemia  
 3.6 Chronic eosinophilic leukemia, not otherwise categorized  
 3.7 Hypereosinophilic syndrome  
 3.8 Mast cell diseases  
 3.9 MPNs, unclassifiable  
4. MDS/MPN  
 4.1 Chronic myelomonocytic leukemia  
 4.2 Juvenile myelomonocytic leukemia  
 4.3 Atypical chronic myeloid leukemia  
 4.4 MDS/MPN, unclassifiable  
5. Myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1  
 5.1 Myeloid neoplasms associated with PDGFRA rearrangement  
 5.2 Myeloid neoplasms associated with PDGFRB rearrangement  
 5.3 Myeloid neoplasms associated with FGFR1 rearrangement (8p11 myeloproliferative syndrome) 
Table 1. The 2008 World Health Organization classification scheme for myeloid neoplasms (Tefferi and 
Vardiman 2008) 
 
This new classification can be called a paradigm shift, because for the first time genetic 
information was incorporated with morphologic, cytochemical, immunophenotypic, and 
clinical information into diagnostic algorithms for the myeloid neoplasms. 
Subsequently this PhD thesis will focus on the subgroup of so-called classic 
myeloproliferative disease or neoplasm, which can be subdivided into Philadelphia 
Chromosome positive (CML) and negative entities (PV, ET, PMF). 
 
3.1.1 Chronic myelogenous leukemia 
Chronic myelogenous leukemia (CML) is a clonal MPN of a pluripotent stem cell with a 
specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, 
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erythroid, megakaryocytic, B lymphoid, and sometimes T lymphoid cells, but not marrow 
fibroblasts (Silver 2003). Concerning the classic MPN, it is by far the most frequent entity 
with an annual incidence of 1.6 per 100,000 people, with slightly more men than women to be 
affected. 
CML has a biphase or triphase clinical course (Medina, Kantarjian, et al. 2003). 
Approximately 90% of patients are diagnosed in the chronic phase, but the disease eventually 
evolves to a blast phase unless successfully treated. Approximately two-thirds of patients 
manifest an accelerated phase. A distinct feature of disease progression, is the appearance of 
additional cytogenetic abnormalities in the Ph- positive cells. This phenomenon, known as 
clonal evolution, frequently involves a second Philadelphia chromosome, trisomy of 
chromosome 8, and isochromosome 17 and other abnormalities of chromosome 17 
(Kantarjian, Dixon, et al. 1988), although other abnormalities have been described. Clonal 
evolution is considered a criterion of accelerated phase, although when it represents the only 
criterion of transformation, it is associated with a better prognosis than other criteria of the 
accelerated phase (Cortes, Talpaz, et al. 2003). 
CML was the first disease where a single chromosomal abnormality, the Philadelphia 
chromosome was demonstrated as fundamental to the etiology of the disease (Nowell and 
Hungerford 1960; Geary 2000). 20 years later De Klein et al. demonstrated that the Abelson 
oncogene (ABL) is translocated from chromosome 9 to chromosome 22 in the formation of 
the Philadelphia chromosome (de Klein, van Kessel, et al. 1982). Although the position of the 
breakpoint in chromosome 9 is quite variable, the breakpoint in chromosome 22 is clustered 
in an area called BCR for breakpoint cluster region.  
The normal cellular BCR gene encodes a 160-kD phosphoprotein associated with serine/ 
threonine kinase activity. The BCR gene is the site of different breakpoints of the known 
alternative forms of the Philadelphia chromosome translocation found in CML and acute 
lymphocytic leukemia (Groffen, Stephenson, et al. 1984; Shtivelman, Lifshitz, et al. 1985; 
Hermans, Heisterkamp, et al. 1987). These alternative breakpoints join different exon sets of 
BCR to a common subset of the exons of the ABL1 gene. This fusion results in mainly two 
alternative chimeric oncogene products called p210(BCR-ABL) and p185(BCR-ABL). The 
activation of ABL tyrosine kinase activity is necessary for the oncogenic potential of the 
chimeric oncogene (Maru and Witte 1991). 
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CML was one of the first and most successful stories for allogeneic transplantation (Hughes, 
Morgan, et al. 1991) and it was in this context that molecular monitoring of so-called minimal 
residual disease (MRD), by sensitive reverse-transcribed polymerase chain reaction (RT-
PCR) techniques was found to be predictive of future relapse (Hughes, Morgan, et al. 1991; 
Lion, Henn, et al. 1993; Radich, Gehly, et al. 1995). Next came the advent of targeted 
tyrosine kinase inhibitor (TKI) therapy, which has quickly replaced transplantation as front-
line therapy for chronic-phase disease. Given the power of molecular monitoring in the 
transplantation setting, molecular monitoring was used in the TKI trials as a measure of 
disease responses. Such monitoring is now advocated for the routine clinical care of CML 
(Radich 2009). 
 
3.1.2 Philadelphia chromosome negative classic myeloproliferative 
neoplasms 
As described above polycythemia vera (PV), essential thrombocythemia (ET) and primary 
myelofibrosis (PMF) as the classic Ph- negative MPN are clonal myeloproliferative 
neoplasms arising from a multipotent progenitor cell.  
The finding of a loss of heterozygosity (LOH) on chromosome 9p in MPN suggested that 9p 
harbors a mutation that contributes to the cause of clonal expansion of hematopoetic cells in 
these diseases. Independently of each other, five groups found that a high proportion of 
patients with these myeloproliferative disorders carried a dominant gain-of-function somatic 
p.V617F point mutation in the JAK2 gene (Baxter, Scott, et al. 2005; James, Ugo, et al. 2005; 
Kralovics, Passamonti, et al. 2005; Levine, Wadleigh, et al. 2005; Zhao, Xing, et al. 2005).  
The Janus family of tyrosine kinases (JAK1, JAK2, JAK3, TYK2) are cytoplasmatic tyrosine 
kinases that mediate signaling downstream of different receptor tyrosine kinase, such as the 
erythropoetin receptor and members of the interleukin receptor family. Normal JAK2 
signaling is important in a number of key cellular processes, such as erythropoesis and 
thrombopoesis and therefore great excitement was caused by the finding of the distinct JAK2 
p.V617F mutation. 
JAK2 p.V617F occurs at a primitive hematopoetic stem cell level in humans (Jamieson, 
Gotlib, et al. 2006), causes impairment of JAK2 regulation and results in the constitutive 
activation of JAK2- STAT5, phosphatidylinositol-3-kinase (PI3K) and mitogen- activated 
 10 
protein kinase / extracellular signal- regulated kinase (MAPK / ERK) downstream signaling 
pathways in a cytokine- independent or hypersensitive manner (James, Ugo, et al. 2005; Lu, 
Levine, et al. 2005; Staerk, Kallin, et al. 2005). 
The revised WHO diagnostic criteria from 2008 for PV, ET and PMF were instigated by the 
discovery of JAK2 mutations in virtually all patients with PV and a major subset of ET and 
PMF (Tefferi 2007). Due to the fact that JAK2 p.V617F is myeloid neoplasm-specific and not 
found in ractive causes of polycythemia, it has lent itself to being a sensitive diagnostic 
marker for PV (Tefferi 2007). However, in the context of myeloid neoplasms, JAK2 p.V617F 
is not specific neither for PV nor for ET and PMF where it is found in approximately 50% of 
the patients. Additionally, it can also be found in refractory anemia with ringed sideroblasts 
associated with marked thrombocytosis (RARS-T) (Ceesay, Lea, et al. 2006; Szpurka, Tiu, et 
al. 2006), and at a lesser frequency in other myeloid neoplasms (Jelinek, Oki, et al. 2005; 
Kremer, Horn, et al. 2006; Lee, Kim, et al. 2006; Nishii, Nanbu, et al. 2007; Zecca, 
Bergamaschi, et al. 2007), but not in lymphoid neoplasms (Fiorini, Farina, et al. 2006; 
Melzner, Weniger, et al. 2006). Therefore, mutation screening for JAK2 p.V617F cannot be 
used to distinguish one MPN from another, but it does complement histology in the diagnosis 
of both ET and PMF by excluding the possibility of reactive thrombocytosis or myelofibrosis. 
Therefore it was considered as a major criteria in the revised WHO classification from 2008 
(Table 2). 
As already described above, the attempt of genetic classification and diagnosis in myeloid 
neoplasms started with the 1960 discovery of the Philadelphia chromosome in CML.  
Additional pathogenetically relevant mutations have been further described in classic and 
non-classic MPNs: JAK2 p.V617F in PV, ET and PMF; JAK2 exon12 mutations in PV (Scott, 
Tong, et al. 2007), MPL p.W515L/K in ET or PMF (Pikman, Lee, et al. 2006), PDGFRA, 
PDGFRB or FGFR1 rearrangements in molecularly characterized myeloid neoplasms 
associated with eosinophilia (Golub, Barker, et al. 1994; Xiao, Nalabolu, et al. 1998; Cools, 
DeAngelo, et al. 2003), KIT p.D816V and other KIT mutations in mast cell diseases (MCD) 
(Nagata, Worobec, et al. 1995) and RAS pathway mutations, including RAS, PTPN11 or NF1, 
in juvenile myelomonocytic leukemia (JMML) (Shannon, O'Connell, et al. 1994; Loh, 
Vattikuti, et al. 2004; Lauchle, Braun, et al. 2006). Such discoveries in the molecular 
pathogenesis of myeloid neoplasms, will ultimately lead to a predominantly genetic 
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classification system with disease-specific molecular markers, that are relevant to both 
diagnosis and treatment (Tefferi and Vardiman 2008). 
 
Table 2. Diagnostic criteria for the classic Ph- negative MPN from WHO 2008 classification (Tefferi and 
Vardiman 2008).  
 
3.2 Molecular pathophysiology of Ph- negative myeloproliferative 
neoplasms 
The above mentioned mutations of JAK2 and MPL are gain-of-function abnormalities that 
conferred growth-factor independency to cells transduced with mutant allele and induced a 
myeloproliferative disease when expressed in murine transplant models (Cazzola and Skoda 
2005; Vannucchi and Guglielmelli 2008). 
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Furthermore, loss of heterozygosity (LOH) for the JAK2 p.V617F mutation, which originates 
from mitotic recombination of the short arm of chromosome 9, is present in approximately 
30% of PV or PMF patients as opposed to 2-4% of ET. Variable proportions of wild-type, 
heterozygous and homozygous progenitors are present in most patients with PV, while 
homozygous progenitors are reported as being rare in ET. Mutated erythroid progenitors are 
more sensitive to erythropoetin than normal ones, and most erythropoetin independent 
erythroid colonies (EEC) are made up of homozygous progenitors. Conceivably, duplication 
of mutant allele is expected to result in a higher level of JAK2/ STAT activation, than in cells 
harboring one mutant and one wild-type allele, possibly because of the loss of competition 
between normal and mutated allele and/ or impaired interaction of mutant JAK2 with cellular 
regulators, such as the suppressor of cytokine signaling-3 (SOCS3) (Hookham, Elliott, et al. 
2007).  
This hypothesis has recently received experimental support, thanks to the successful 
development of conditional transgenic mice, that expressed variable levels of JAK2 p.V617F 
(Tiedt, Hao-Shen, et al. 2008), in which the phenotype closely reflected the ratio between 
normal and mutated JAK2 mRNA. Likewise, the p.V617F allele burden correlates with 
hematologic characteristics and clinical endpoints in MPN patients. However, owing to the 
wide distribution of individual values, it seems quite unlikely that load of mutant p.V617F 
allele alone represents the key mechanism at the basis of MPD pleiotropy, although it is likely 
that changes in p.V617F allele burden correlate with disease progression (Vannucchi, 
Antonioli, et al. 2008).  
There is evidence to support the possibility that disease alleles other than JAK2 p.V617F 
or MPL p.W515L/K are involved in the pathogenesis of MPNs (Skoda 2007), in addition to 
the fact that almost 40% of ET or PMF patients still lack a molecular marker. First, 
discrepancies were found in the size of del(20)q and JAK2 p.V617F- mutated clones, leading 
to the suggestion that p.V617F allele had been acquired by a pre-existing del(20q) clone and 
can be seen as a rather late event in the progress of the malignancy (Kralovics, Teo, et al. 
2006). Second, EEC wild-type for JAK2 have been detected at low frequency in PV 
patients, which would indicate the JAK2 mutation is a secondary, not a disease-initiating, 
genetic event (Nussenzveig, Swierczek, et al. 2007). Third, the incidence of MPNs among 
relatives is greater than expected in the normal population, but neither the diagnosis of MPN 
nor the distinct clinical phenotype encountered in these families were invariably associated 
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with the presence of JAK2 or MPL mutation, suggesting that these mutations might occur as a 
secondary genetic event on the background of an inherited genetic predisposition (Rumi, 
Passamonti, et al. 2006). Finally, blast cells of secondary acute myeloid leukemia that 
developed in patients with a preceding JAK2 p.V617F-positive MPN are often JAK2 
p.V617F- negative, indicating that they might derive from the transformation of a pre-JAK2 
p.V617F mutated hematopoetic stem cell which was originally at the basis of the MPN itself 
(Campbell, Baxter, et al. 2006). However, that these JAK2 p.V617F negative blasts 
represented the de-novo transformation of a residual normal progenitor cannot be excluded on 
the basis of available data. After all, it is more unlikely that the JAK2 un-mutated blasts 
originated from a single cell, heterozygous for the p.V617F mutation that underwent a 
reverse mitotic recombination process, leading to an un-mutated JAK2 genotype. On the 
contrary, the possibility that the JAK2 p.V617F and MPL mutation alone might be sufficient 
for causing an MPN is compellingly supported by the results of animal models, including the 
recently described transgenic mice, that developed phenotypes closely resembling human ET 
and PV and presented MF-like symptoms as they aged (Xing, Wanting, et al. 2008). 
 
3.3 Molecular diagnostics of myeloproliferative neoplasms 
The spectacular finding of the Philadelphia Chromosome in CML opened new avenues in 
pathophysiological research and was the initiation of molecular diagnostics. The initial 
molecular diagnosis can be done performing cytogenetics, fluorescence in situ hybridization 
(FISH), southern or western blot and RT-PCR. Noteworthy to mention, that cytogenetic 
diagnostics alone is not sensitive enough to detect the Ph in all of the cases, but still remains 
the gold standard in most cases. 
The new field of the merge of diagnostic and therapy called theragnostic for hematologic 
disease was invented a decade ago with imatinib mesylate in 1998, the first tyrosine kinase 
inhibitor (TKI) (Hughes and Branford 2009). It received international attention as a promising 
new "targeted" therapy for disease control in patients with advanced-phase CML and 
interferon- refractory chronic-phase disease. Targeted therapy is defined as a drug with a 
focused mechanism that specifically acts on a well-defined target or biological pathway 
which, when inactivated, causes regression or destruction of the malignant process (Ross, 
Schenkein, et al. 2004). The obvious advantage of such therapies is that they are less toxic, 
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with a higher therapeutic index and potentially more effective. Moreover, the application of 
these therapies is usually limited to patients known to carry the appropriate molecular target 
in their malignant cells, therefore eliminating the toxic and financial implications of more 
generalized use. While in some circumstances these new therapies will eliminate the need for 
traditional chemotherapy regimens, in other cases, it is likely that they will lower the 
threshold for induction of programmed cell death, thus enhancing the effectiveness of 
conventional chemotherapy approaches (Hamilton, Gallipoli, et al. 2010). 
Imatinib mesylate functions by competitive inhibition of the adenosine triphosphate (ATP) 
binding site, thereby preventing BCR-ABL autophosphorylation, TK activity and subsequent 
phosphorylation of downstream target substrates and appears to selectively induce apoptosis 
in BCR-ABL- positive cells. Five year follow-up studies have shown sustained benefit for 
imatinib mesylate treated patients. Despite the success of Imatinib, a major clinical concern is 
the observation of molecular resistance, most often attributed to the development of point 
mutations within the ABL- kinase domain. To date, more than 50 kinase mutations have been 
described in vivo and from in vitro screens (Branford 2007). These include mutations which 
prevent BCR-ABL from adopting the inactive conformation required for Imatinib binding. In 
an attempt to overcome Imatinib resistance, a second generation of BCR-ABL inhibitors has 
been developed. Nilotinib inhibits ABL- kinase with a 20-50- fold greater potency than 
Imatinib. Like Imatinib, Nilotinib binds the inactive form of BCR-ABL, but has alterations in 
its structure that allow higher binding affinity. Dasatinib is a second- generation TKI for the 
treatment of Imatinib- resistant or –intolerant patients with Ph- positive leukemias, which was 
approved by the FDA in 2006 (Talpaz, Shah, et al. 2006). Dasatinib is a potent oral inhibitor 
of SCR family kinases and BCR-ABL, and has added activity against KIT- receptor, platelet- 
derived growth factor receptor (PDGFR) and ephrin receptor tyrosine kinase (Lombardo, Lee, 
et al. 2004). Dasatinib has a 325- fold greater potency than Imatinib against cells expressing 
wild-type BCR-ABL and is able to bind both the active and inactive conformation of ABL- 
kinase (Tokarski, Newitt, et al. 2006).  
Today, Imatinib represents the established front-line therapy for nearly all patients with CML, 
achieving near- normal survival and quality of life and second-generation TKIs are usually 
the preferred option in cases of Imatinib failure. The need for frequent ongoing monitoring for 
these long-term responders now warrants reassessment. However, up to 30% of patients with 
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CML will have to stop Imatinib therapy due to intolerance and resistance (Jabbour, Cortes, et 
al.). Therefore close monitoring still has a vital role. 
A risk-adapted monitoring strategy is implemented to ensure cost-effective management for 
all patients. The main aim of monitoring response to TKI therapy is, to identify patients who 
can be reassured that they have achieved a stable remission and, perhaps more 
importantly, those who are likely to achieve better long-term outcome, if they are switched to 
second-line therapy. This may be another TKI or in some specific cases an allogeneic stem 
cell transplant. Apparent loss of cytogenetic or molecular response can sometimes be 
attributed to variations in assay values or short-term lapses in compliance (Hughes and 
Branford 2009). 
Monitoring response to TKI therapy relies on (1) bone marrow cytogenetic analysis in the 
first 12 to 18 months, as well as (2) regular measurement of the BCR-ABL transcript levels by 
reverse transcriptase quantitative PCR (RT-QPCR) assays plus (3) selective testing for BCR-
ABL kinase domain mutations. Monitoring strategies during first-line therapy have been 
reviewed recently and reasonable consensus has been achieved (Baccarani, Pane, et al. 2008; 
Kantarjian, Schiffer, et al. 2008; Hughes and Branford 2009).  
In 2006 an international scale (IS) for expressing BCR-ABL RT-QPCR results was proposed 
(Hughes, Deininger, et al. 2006). This was linked to recommendations for optimizing 
methodology, including a detailed review of the merits of sampling blood versus bone 
marrow and optimal volume and preparation of blood samples. In-house methods could be 
continued because local values were converted to the IS, using a conversion factor derived 
from a comparison between the BCR-ABL levels calculated from a set of shared patient 
samples studied in the local laboratory and a reference laboratory (Branford, Fletcher, et al. 
2008). This process has enabled over 50 laboratories to express their results as BCR-
ABL level (IS). This allows clinicians to determine whether their patient has achieved specific 
molecular landmarks (  0.1% = major molecular response [MMR]; 1% is approximately 
equivalent to a complete cytogenetic response [CCR]). However, reporting BCR-ABL values 
on the IS does not give an indication of the measurement reliability or the sensitivity of the 
local RT-QPCR assay, issues that will also impact on the clinical value of RT-QPCR assays. 
Compared to molecular diagnostics or theragnostics for CML, the situation concerning the 
classic Ph- negative MPN is in the fledging stages. We are far away from standardization or 
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certification of molecular diagnostic methods concerning the relevant genomic aberrations of 
the JAK2 and MPL gene. As mentioned above, the JAK2 Exon14 p.V617F point mutation will 
be detected in cases of PV in 82%, ET in 49% and in PMF in 53% (Hussein, Bock, et al. 
2007). Many different PCR- based detection methods are described, all of them with their 
specific limitations mainly concerning sensitivity, because of the competitive situation with 
the wild type allele.  
Currently, a number of agents to inhibit JAK2, such as XL019 (Shah, Olszynski, et al. 2008), 
INCB018424 (Verstovsek, Kantarjian, et al. 2008), TG101348 (Lasho, Tefferi, et al. 2008; 
Wernig, Kharas, et al. 2008), CEP-701 (Verstovsek, Tefferi, et al. 2007) and also Erlotinib 
(Li, Xu, et al. 2007), are in preclinical development and clinical trials. INCB018424 is the 
clinically most extensively studied JAK2 inhibitor. It is an orally, bioavailable selective 
inhibitor of JAK1 and JAK2 at nanomolar concentrations, which entered early- phase clinical 
trials in 2007. Patients treated with INCB018424, demonstrated a significant reduction in 
spleen size and also other constitutional symptoms, were either resolved or were significantly 
reduced (Verstovsek, Kantarjian, et al. 2008). CEP-701 (Lestaurtinib) is an orally active small 
molecule inhibitor of receptor tyrosine kinase, including fms- related tyrosine kinase (FLT3) 
(Levis, Allebach, et al. 2002) and JAK2, and is currently in phase II clinical trials for patients 
with PMF and post- PV / ET myelofibrosis who have the JAK2 p.V617F mutation 
(Verstovsek, Tefferi, et al. 2007).  However, it is of importance that specific inhibitors to 
mutated JAK2 are generated to minimize general toxicity and long- term side affects. 
Preliminary studies have shown, that the suppression of the JAK- STAT- pathway can lead to 
treatment- related thrombocytopenia and anemia (Verstovsek, Kantarjian, et al. 2008). 
Despite these concerns, targeting JAK2 represents a promising option for the treatment of 
BCR-ABL- negative MPN. 
 
Normally the clinical test for detection of the JAK2 p.V617F mutation is performed on 
peripheral blood, bone marrow aspirates or formalin- fixed- paraffin- embedded (FFPE) bone 
marrow core biopsies. All of them consist of mixed cellular material with just a fraction of 
JAK2 p.V617F positive cells, either hetero- or homozygote. This is a serious problem, mainly 
in the initial stadium of the diseases and in case of myelofibrosis when the malignant tissue is 
relatively repelled by reactive mesenchymal proliferation. In those cases sanger sequencing 
with a sensitivity of 20% will produce false negative results (Adamson, Fialkow, et al. 1976; 
Sanger, Nicklen, et al. 1977).  Remaining techniques like restriction fragment length 
polymorphism (RFLP) PCR, amplification refractory mutation system (ARMS) PCR and 
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fluorescent probes SNP QPCR, will all fit the necessary sensitivity for reliable initial 
diagnosis (Kroger, Badbaran, et al. 2007; Shammaa, Bazarbachi, et al. 2010). Also the 
upcoming method of pyrosequencing is a powerful tool for sensitive detection of point 
mutations (Ronaghi, Karamohamed, et al. 1996; Ronaghi, Uhlen, et al. 1998; Ronaghi 2001; 
Hochberg, Miklos, et al. 2003). 
This is also true for diagnosis of the MPL point mutations, but the in part more complex 
mutations in JAK2 Exon12 will require conventional sequencing methods because of possible 
negative results from PCR probes, since they are designed especially for known aberrations. 
The situation dramatically changes in the case of patients after hematopoetic stem cell 
transplantation, because of the therapy related strong decrease of malignant cells. Here, for 
detection of minimal residual disease a sensitivity of at least 0.01% is needed, which can be 
only provided by few assays (Kroger, Badbaran, et al. 2007; Siebolts, Lange, et al. 2010). 
Future inventions of targeted therapy will surely come back to these sensitive assays. Like in 
CML, it will be a fundamental goal to define standardized protocols of robust techniques, in 
international collaborating diagnostic laboratories. 
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4. Aims and major findings of this PhD thesis 
 
4.1 Aims 
One aim of the study performed on this PhD thesis was to shed new light on aspects of the 
pathophysiology of MPN. Therefore we started with characterization and quantification of 
CD34- positive progenitor cells from PV as the source of these diseases. Additionally we 
performed a cDNA- array study on this particular and rare cell type in order to find molecular 
mechanisms causing PV besides the JAK2 p.V617F point mutation. 
Furthermore we focused on characterization of host hematopoesis after stem cell 
transplantation (SCT) in patients suffering from MPN and particular in developing robust and 
sensitive diagnostic assay for reliable detection of minimal residual disease (MRD). 
 
4.2 Major findings 
(1) Primitive hematopoesis is altered in PV because untreated peripheral blood CD34- 
positive progenitor cells in this disease display more pleomorphic size and, during in vitro 
maturation, a delayed expression of differentiation markers. 
(2) CDNA microarray analysis on CD34- positive peripheral blood cells of PV patients 
revealed an imbalance of DNA-dependent protein kinase subunits which may contribute to 
the accumulation of chromosomal aberrations, accumulation of hematopoetic cells, and 
prolongation of CD34- positive peripheral blood cells life span. 
(3) In untreated PV patients with trisomy eight of nine, CD34- positive peripheral blood cells 
consisted almost exclusively of neoplastic cells but with the finding of a distinct, 
cytogenetically normal, CD34- positive progenitor cell population in chronic phase PV which 
may offer perspectives in treatment of the disease. 
(4) After successful hematopoetic stem cell transplantation following reduced intensity 
conditioning in patients with MPN the hematopoetic compartment revealed an almost 
complete chimerism of the mature hematopoesis whereas CD34- positive cells remained of 
recipient origin to a higher proportion. Furthermore, the recipient CD34- positive cell 
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population in case of CML disposes of better strategies to escape immune surveillance than in 
PMF. 
(5) Since reliable detection of minimal residual disease becomes more and more important in 
MPN patients after hematopoetic stem cell transplantation more sensitive assays are urgently 
needed. In combination of a robust QPCR with increased sensitivity up to 1x 10^5 performing 
wild- type blocking PCR we could invent a powerful tool for detection of MRD. 
(6) Broad retrospective research in miRNA expression profile is exclusively possible hark 
back to the large archives of formalin fixed paraffin embedded material all over the world. 
Here, we could show for the first time that extraction of sufficient amount of miRNA even on 
decalcified specimens and after decades is possible. 
 
5. Present investigation 
5.1 Structural, antigenetic and transcriptional characteristics in 
peripheral blood CD34+ progenitor cells from polycythemia vera 
patients: evidence for delayed determination (Wickenhauser C., 
Perez F., Siebolts U., et al. Int J Oncol. (2003): 23, 437-443) 
Prior to the evidentiary finding of a neoplastic stem cell character of Ph- negative MPN there 
was a gap of knowledge concerning this fundamental cell compartment.  What was known is 
that PV progenitor cells are hypersensitive to several growth factors although their receptor 
expression is reduced or absent (Dai, Krantz, et al. 1991; Dai, Krantz, et al. 1992; Dai, Krantz, 
et al. 1994). To reveal the underlying mechanisms of this peculiarity we compared frequency, 
morphology, antigen expression, transcription of differentiation markers and proliferation as 
well as apoptosis rate following short term culture of selected CD34- positive peripheral 
blood cells from PV patients, healthy donors and patients with secondary polycythemia.  
The highest amount of CD34- positive cells was found in the group of patients with secondary 
polycythemia by simple cell metering while the frequency was slightly lower but more 
variable in PV. By performing light microscopy, morphometry and transmission electron 
microscopy we found native PV CD34- positive cells varying in shape and form and a 
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decrease amount of intracytoplasmatic organelles like mitochondria and a more extended 
Golgi apparatus while in the other groups they constituted a uniform phenotype. However 
performing RT-PCR, no transcripts for Glycophorin A (GypA) and CD41b, both markers for 
advanced erythropoesis and megakaryopoesis, could be detected in sorted PV progenitors. 
Also, coexpression for early acting hematopoetic cytokine receptors IL-3R and KIT and for 
initial erythropoesis (GYPC) or megakaryopoesis (CD61) was similar in the different groups 
using additional FACS analysis. Performing 96 h cocultures with bone marrow fibroblasts the 
frequency of CD34- positive cells was elevated, downregulation of IL-3R delayed 
coexpression of GYPC reduced and proliferative activity higher in the PV group.  
In conclusion our results suggest that primitive hematopoesis is altered in PV because PB 
CD34- positive cells in this disease are characterized by a maturation dissociation with 
increased activation in untreated populations and a delayed differentiation in short-term 
cultures. 
Own contributions:  
Together with Prof. Dr. Wickenhauser I was involved in study design and conception. 
Methodically I performed the cell preparation of mononuclear cells and subsequent 
enrichment of CD34 positive hematopoetic cells by magnetic activated cell sorting (MACS) 
on fresh blood samples from healthy donors, patients with PV or secondary polycythemia. 
Moreover, I was involved in analyzing the stained paraffin sections and performing FISH 
technique with subsequent microscopic examination. 
 
5.2 Quantification of clonal hematopoiesis in polycythemia vera 
(Siebolts U., Ates M., Spitz R., et al. Virchows Arch. (2005): 447, 947-
953) 
This work was done before the spectacular awareness of specific genomic aberrations and 
especially the finding of the distinct point mutation in the JAK2 gene p.V617F in the 
pathophysiology of Ph- negative MPN. Until then there was only not proven evidence for the 
clonal stem cell origin of these entities that causes the accumulation of morphologically 
normal red cells, white cells, platelets, and their precursors in the absence of a definable 
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stimulus (Spivak 2002). This study was undertaken not only to estimate for the first time the 
proportion of the neoplastic cells compared to the residual nonneoplastic CD34- positive cells 
but also to ascertain new evidence for the clonal origin. 
Therefore, we screened peripheral blood mononuclear cells of PV patients in the chronic 
phase of the disease and looked for chromosomal abnormalities performing comparative 
genomic hybridization. Two of ten patients under study revealed cytogenetic changes, 
including trisomy 8 or 9. These findings enabled us to quantify the proportion of abnormal 
clonal cells by applying fluorescence in situ hybridization (FISH) technique. Ninety percent 
of the mononuclear cells and up to 79% of PB- derived CD34- positive cells presented three 
signals for chromosome 8 or 9. Although the probability to detect FISH signals in a certain 
section plane is reduced, constantly 10 – 15% of the cells revealed three signals. Concerning 
the CD34- positive cell pool, a distinct population without cytogenetic aberrations exists in 
these patients. Our data underline the clonal character of PV and additionally quantify the 
proportion of clonal CD34- positive cells for the first time. Furthermore, the finding of a 
distinct, not aberrant, CD34- positive cell population in chronic phase PV may offer 
perspectives in treatment of the disease. 
Own contributions: 
Initially I performed the cell preparation of mononuclear cells and subsequent enrichment of 
CD34- positive hematopoetic cells by magnetic activated cell sorting (MACS) on fresh blood 
samples from healthy donors, patients with PV or secondary polycythemia. Moreover, I was 
involved in analyzing the stained paraffin sections and performing FISH technique with 
subsequent microscopic examination. 
 
5.3 Dualism of mixed chimerism between hematopoiesis and 
stroma in chronic idiopathic myelofibrosis after allogeneic stem cell 
transplantation (Thiele J., Varus E., Siebolts U., et al. Histol 
Histopathol. (2007): 22, 365-372) 
Since hematopoetic stem cell transplantation is the only curative therapeutic approach for 
patients with Ph- negative MPN scant knowledge exists concerning mixed chimerism 
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following therapy (Deeg, Gooley, et al. 2003).  However, controversy continues about the 
donor or host origin of stroma constituents following myeloablative therapy and subsequent 
transplantation (Simmons, Przepiorka, et al. 1987; Athanasou, Quinn, et al. 1990; Santucci, 
Trabetti, et al. 1992). Because of the gate keeper function of stromal endothelial cells by 
controlling the trafficking and homing of progenitors the possible neoplastic origin and its 
frequency of this cell compartment is of special interest (Simmons, Masinovsky, et al. 1992; 
Mohle, Bautz, et al. 1999).  
Following a sex- mismatched peripheral blood stem cell transplantation of PMF patients, a 
combined immunopheno- and genotyping by FISH was performed on sequential bone marrow 
biopsies at standardized intervals. Results were compared with PCR based chimerism analysis 
of corresponding peripheral blood samples in five patients.  
According to FISH, pretransplant specimens revealed a gender congruence of more than 99%, 
while in the first three month the total bone marrow exhibited a persistent fraction of host 
cells (30% to 40%) with a tendency to decline after about one year. Although the 
hematopoetic compartment (CD34 and CD61- positive cells) exhibited only very few host- 
derived cells which states an almost complete chimeric (donor- derived) hematopoesis and 
therefore a successful transplantation. Concerning the stromal cells and especially the 
endothelial cells we could show that the majority of these cells maintained recipient origin. In 
keeping with the prevalence of donor cells in the hematopoetic compartment, PCR- data of 
peripheral blood displayed a non- significant degree of mixed chimerism. 
Own contributions: 
I was involved in analyzing the stained paraffin sections and performed FISH analysis with 
subsequent microscopic examination. 
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5.4 Differences in proportion and dynamics of recipient 
hematopoiesis following hematopoietic cell transplantation in CML 
and IMF (Siebolts U., Thiele J., Zander T., et al. Oncol Rep. (2008): 
19, 287-292) 
Since decades myeloablation followed by allogeneic stem cell transplantation offered the only 
opportunity to cure leukemia patients and only recently the development of STI571 (Imatinib) 
created a further alternative in CML. Generally, two variation of transplantation regimen 
exist, hematopoetic stem cell transplantation with antecedent conventional myeloablative or 
the newly upcoming reduced intensity conditioning (RIC). The application of conventional 
myeloablative hematopoetic stem cell transplantation has, amongst others, been limited by the 
age of the recipient because of its possible complications. Therefore, the use for RIC offers an 
optional curative therapy also for older and fragile patients.  
While among all leukemias the conventional transplantation regimen had the best outcome in 
CML, trials with RIC were rather humbling and recurrence of the neoplastic clone occurred 
frequently. However, the same therapy in patients with PMF resulted in a more favorable 
outcome. In an approach to reveal the underlying mechanisms of this discrepancy long- term 
mixed chimerism was determined on bone marrow biopsies derived from five PMF patients 
and from eight CML patients of the pre Imatinib era following sex- mismatched 
transplantation.  
Despite nearly complete chimerism after stem cell transplantation in mature hematopoesis, 
analysis of late transplant period revealed a concentration of host cells within the CD34- 
positive cell compartment in both diseases. However, in PMF bone marrow biopsies only up 
to 8% recipient CD34- positive cells but in CML biopsies up to 26% recipient CD34- positive 
cells were detected despite the myeloablative regimen in case of CML patients. Taken into 
account that in CML up to 10% of the host bone marrow CD34- positive cells bear the BCR-
ABL translocation, our data suggest that the neoplastic CD34- positive cell population might 
dispose of better strategies to escape immune surveillance in CML than in IMF. 
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Own contributions: 
Based on the antecedent study I had the idea of a comparative study of RIC and myeloablative 
regimen. Methodically, I was involved in analyzing the stained paraffin sections and 
performed FISH analysis with subsequent microscopic examination and further in conception 
of the study. After all I performed data analysis and graphical illustration. 
 
5.5 Imbalance of DNA-dependent protein kinase subunits in 
polycythemia vera peripheral blood stem cells (Siebolts U., 
Breuhahn K., Hennecke A., et al. Int J Cancer. (2009): 124, 600-607) 
The above listed publications published within this doctoral thesis are dealing with different 
aspects of pathophysiology and therapeutic aspects of MPN. The recurrent finding of 
interesting results together with distinct hints of international scientific literature concerning 
the CD34- positive progenitor cell compartment again focused our intensified interest on this 
cell population.  
Since the specific JAK2 p.V617F point mutation represents a rather late event in the disease 
progression, is not specific for this disease, and is not ascertained in all patients indicating that 
additional factors contribute to the specific phenotype of PV, we tried to reveal undescribed 
aberrations (Baxter, Scott, et al. 2005; Kralovics, Passamonti, et al. 2005; Kralovics, Teo, et 
al. 2006; Nussenzveig, Swierczek, et al. 2007). Therefore, cDNA microarray analyses were 
performed on CD34- positive peripheral blood stem cells with subsequent evaluation on 
mRNA and protein level of a larger cohort of PV patients. Microarray analyses revealed a 
significant dysregulation of 11 genes. KU86, a gene coding for a subunit of the DNA-
dependent protein kinase (DNA-PK), displayed the strongest upregulation in all patients 
under study. This peculiarity was accompanied by downregulation of the catalytic DNA-PK 
subunit DNA-PKcs. Also KU86 protein was upregulated and expressed in the vast majority of 
CD34- positive peripheral blood stem cells nuclei while a weak nuclear expression was 
detected in only one blood donor. Differential expression of several genes, imbalance of the 
distinct subunits of DNA-PK, and particularly the strong upregulation of KU86 protein, are 
new findings in PV CD34- positive peripheral blood stem cells. These factors may contribute 
to the accumulation of chromosomal aberrations, accumulation of hematopoetic cells 
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(especially of erythropoesis), and prolongation of CD34- positive peripheral blood stem cell 
life span observed in PV. 
Own contributions: 
Prior to the lab work I have done most of the study conception and design together with Prof. 
Dr. Wickenhauser. Initially I performed the cell preparation and enrichment of CD34- 
positive hematopoetic cells by magnetic activated cell sorting (MACS) on fresh blood 
samples from healthy donors, patients with PV or secondary polycythemia. Moreover, I have 
done all subsequent steps of DNA, RNA and Protein preparation, reverse transcription, primer 
design, radioactive cDNA array hybridization, RT-QPCR, Western Blot and all subsequent 
analysis and graphical illustration of the data inclusive the statistical evaluation. Further I was 
involved in microscopic examination of the stained paraffin sections. 
 
5.6 Tissues from routine pathology archives are suitable for 
microRNA analyses by quantitative PCR (Siebolts U., Varnholt H., 
Drebber U., et al. J Clin Pathol. (2009): 62, 84-88) 
Plenty of expert knowledge in handling of decalcified formalin fixed paraffin embedded 
tissue could be acquired of our group in the last years. Especially the sufficient extraction of 
RNA, normally highly degenerated, make high demands on staff and laboratory skills.  
However, since molecular diagnostics on formalin fixed paraffin embedded (FFPE) material 
becomes more and more important numerous studies focused on detection of new specific 
molecular peculiarities suitable for diagnostic purpose. In this context the new finding of so 
called microRNA (miRNA) invented a new enthusiasm in finding specific dysregulated 
groups of miRNA which can be used as a diagnostic means since cDNA- array clustering 
often leads to a dead end. 
A prerequisite for using the large archives of FFPE tumor material all over the world for not 
only scientific but also for diagnostic purpose is the certain accessibility of miRNA out of this 
particular material even in the challenging case of osseous bone marrow biopsies. 
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Therefore we tested the accessibility of two representative miRNAs examined by RT-QPCR 
in 86 human FFPE samples from liver, breast, bone marrow, lymphatic tissue and colon. 
Murine liver was used to analyze the influence of fixation time and different fixatives. 
Briefly, extraction of sufficient amount of miRNA was possible in all cases. Storage of human 
tissues for up to seven years did not cause a significant deterioration of miRNA. However, 
miRNA quality in human archival material following routine processing 10 – 20 years ago 
was decreased but still sufficient for downstream applications. Oxidation by ambient air 
during storage and fixation in non-buffered formalin is a possible reason for loss of miRNA 
quality. 
Therefore, the assessment of miRNA in readily obtained FFPE samples is a highly promising 
tool in molecular pathology when similarly treated samples are analyzed.  
Own contributions: 
Together with Dr. Odenthal and Dr. Varnholt I have participated upon the study conception 
and design. Mostly I was involved in analysis of miRNA RT-QPCR inclusive the statistical 
evaluation and graphical illustration of the data. 
 
5.7 Allele-specific wild-type blocker quantitative PCR for highly 
sensitive detection of rare JAK2 p.V617F point mutation in primary 
myelofibrosis as an appropriate tool for the monitoring of molecular 
remission following therapy (Siebolts U., Lange T., Niederwieser D., 
et al. J Clin Pathol. (2010): 63, 370-372) 
 
Since the invention of reduced intensity conditioning (RIC) regimen prior to hematopoetic 
stem cell transplantation improved the accessibility for curative therapy to patients with Ph- 
negative MPN with myelofibrosis it became more and more important to detect minimal 
residual disease (MRD) as sign of relapse. In case of patients harboring the specific JAK2 
p.V617F mutation monitoring of this mutation on peripheral blood or even on formalin fixed 
paraffin embedded bone marrow biopsies can be utilized for this purpose. Because of the 
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therapy related strong decrease of malignant cells a prerequisite for detection of MRD is a 
sensitivity of the methodological approach of at least 0.01% which means 1 mutated allele on 
a background of 10,000 wildtyp alleles. 
In an attempt to achieve the required high sensitivity, specifity and robustness we created an 
approach applicable also on bone marrow biopsies where we adapted the principle of wild- 
type blocker PCR with allele- specific QPCR. The significance of the assay was demonstrated 
on a retrospective series of sequential bone marrow biopsies as diagnosis of molecular relapse 
now preceded the diagnosis of clinical relapse by far. This method offers the urgently needed 
tool for a systematic molecular analysis of sequential biopsies in the course of stem cell 
transplantation to develop guidelines for the management of these patients. 
Own contributions: 
Initially I have had the idea of using MGB- Taqman Probes for detection of the wild- type and 
the mutated allele on the same amplified strand together with performing a two step approach 
with initial wild- type blocking PCR for increased sensitivity. Moreover, I have done all 
subsequent steps of design, laboratory work and in silico processing. 
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6. Progress and further activities during the PhD thesis 
In addition to my PhD thesis I was further involved in routine diagnostics pathology within 
my specialist training since 2004 in the Institute of Pathology, University Hospital of Cologne 
and since 2008 in the Institute of Pathology, University Hospital of Leipzig. However, 
particular attention was paid to the special subject of molecular pathology and in 2009 I 
became laboratory head of molecular diagnostics, Institute of Pathology. In this context, I was 
able to place the invented methods directly into the routine diagnostics and furthermore to 
develop new methods especially availing the upcoming technology of pyrosequencing. 
Together with scientists of the Department of Hematology / Oncology, University Hospital of 
Leipzig we screened 20 MPN patients for minimal residual disease after stem cell 
transplantation with the above described technique (Siebolts, Lange, et al. 2010) and tested 
each sample in the molecular laboratory of the Department of Hematology / Oncology 
performing ARMS- PCR. The data were correlated not only with the clinical outcome but 
also with the corresponding information of donor chimerism of the same samples which also 
were detected in our laboratory. A manuscript of the data currently is submitted for 
publication. 
As described above the entity of mastocytosis, as a part of MPN, is mostly combined with the 
finding of the KIT p.D816V point mutation, which serves also as a diagnostic means. 
Analogous to the allele- specific wild- type blocking QPCR we tried to design a highly 
sensitive and reliable method for detection of the KIT p.D816V point mutation using the 
challenging paraffin embedded and decalcified bone marrow biopsy specimen as the DNA- 
source. Therefore we designed a specific wild- type blocking LNA modified DNA probe 
applying in a first round PCR. Subsequently a second PCR in preparation of pyrosequencing 
will be performed. Finally, this approach together with samples without wild- type blocking 
PCR gives information about the allelic burden of KIT p.D816V and also has the necessary 
sensitivity in case of a low tumor cell burden which is mostly pathognomonic for 
mastocytosis. Meanwhile, this technical approach has found its way into the routine 
diagnostis of our Institute. 
Another new molecular diagnostics technique under construction in collaboration with the 
Department of Ophthalmology is the detection of monosomy of chromosome 3 in diagnostic 
specimen of patients suffering from uveal melanoma. Uveal melanoma is the most common 
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primary intraocular tumor, with an annual incidence of six per one million. About 50% of 
uveal melanoma carry chromosome 3 monosomy, which, together with tumor stage and 
spindle shaped versus epitheloid subtype, has been shown to be a significant predictor of 
metastatic disease and poor prognosis. To date cytogenetics, comparative genomic 
hybridization and microsatellite analysis have been used to identify chromosomal aberrations 
in uveal melanoma. However, these methods are costly, time consuming, difficult to interpret 
and mostly require ample tumor material, which is hardly to reach by diagnostic fine needle 
aspirates (FNA). Therefore we want to establish a reliable, easy to use method on FNA with 
first, evaluation of the histological subtype and second, subsequent DNA extraction and 
testing for monosomy 3. 
In a first step, DNA can be extracted from FNA- smears and from blood of the respective 
patients. Blood DNA then is screened for informative because heterozygous SNP loci on 
chromosome 3 performing pyrosequencing. Accordingly, data will be compared with those 
obtained by tumor DNA analysis. In case of pseudo- homozygous conversion of the tested 
SNP, allele- loss and therefore monosomy can be stated.  For verification of the method 
further fluorescence in situ hybridisation (FISH) will be performed. This approach of micro- 
invasive FNA combined with the technique of allele specific SNP pyrosequencing is highly 
sensitive, reliable, easy to use and interpret, fast to perform and cost- effective. However, in 
the meantime the described assay employing tissue from eye enucleates is part of the routine 
molecular diagnostics of our institute. 
 
6.1 Awards / Talks 
Siebolts U., Breuhahn K., Schultze J.L., Thiele T., Wickenhauser C. CD34+ cells from 
polycythemia vera patients reveal dysregulation of regulators of hematopoesis, apoptosis, cell 
cycle and DNA repair. First prize poster presentation, Oncology Symposium of the Cologne 
Fortune Foundation. July 15th, 2003, Cologne. 
Siebolts U., Breuhahn K., Schultze J.L. and Wickenhauser C. CD34+ cells from 
polycythemia vera patients reveal dysregulation of regulators of hematopoesis, apoptosis, cell 
cycle and DNA repair. 88th Annual Meeting of the German Society of Pathology (DGP). June 
2 – 5, 2004, Rostock. 
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Siebolts U., Lange T. and Wickenhauser C. Monitoring of patients with JAK2 p.V617F 
positive primary myelofibrosis by allele-specific wild-type blocker QPCR. Annual Fall 
Meeting of the East- German Study Group for Hematology and Oncology (OSHO). 
November 21 – 22, 2008, Leipzig. 
Siebolts U., Al-Ali HK., Niederwieser D., Wickenhauser C. Establishment of a highly 
sensitive allele specific wild type blocker polymerase chain reaction followed by 
pyrosequencing for detection of the KIT p.D816V point mutation. Annual Meeting of the 
American Society of Hematology (ASH). Meeting Abstract. December 4 – 8, 2009, New 
Orleans, Blood 114, 4975. 
Lange T., Edelmann A., Siebolts U., Nehring C., Jäckel N., Cross M., Maier J., Niederwieser 
D., Wickenhauser C. Milestones of Post Transplant Monitoring of JAK2 p.V617F Positive 
MPN Patients. Annual Meeting of the American Society of Hematology (ASH). Poster 
Abstract. December 4 – 8, 2010, Orlando, Blood 116, 3462. 
Siebolts U. and Wickenhauser C. Theragnostic – Prerequisite for a personalized medicine. 
Regulars’ Table Life Science of Bio City Leipzig and Chamber of Industry and Commerce 
Leipzig. September 15, 2010, Leipzig. 
Siebolts U., Lange T. and Wickenhauser C. Allele specific PCR for the JAK2 p.V617F 
mutation is a valuable approach to detect residual disease in patients after hematopoetic stem 
cell transplantation. 94th Annual Meeting of the German Society of Pathology (DGP). May 
27 – 30, 2010, Berlin. 
Siebolts U. and Wickenhauser C. Establishment of a highly sensitive allele specific wild type 
blocker polymerase chain reaction followed by pyrosequencing for detection of the KIT 
p.D816V point mutation. 3rd Novartis Oncology Advent Symposium. November 19 – 20, 
2010, Eisenach. 
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7. Additional publications during the PhD thesis 
During my PhD thesis I took part of diverse scientific collaborations leading to several 
publications listed below. Mostly I was involved in molecular analysis performing different 
PCR- based techniques and fluorescence in situ hybridization (FISH). Also, analyzing of 
stained paraffin sections and interpretation of immunochemistry and furthermore statistical 
analysis and graphical illustration was part of my contribution. 
Kappert K., Sparwel J., Sandin A., Seiler A., Siebolts U., Leppanen O., Rosenkranz S. and 
Ostman A. Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in 
cultured VSMCs and in restenosis. Arterioscler Thromb Vasc Biol. 2006: 26, 2644-51. 
Own contributions: 
I was involved in analyzing the stained paraffin sections and semiquantitative analysis of the 
immunochemistry. 
 
Gerharz M., Baranowsky A., Siebolts U., Eming S., Nischt R., Krieg T. and Wickenhauser C. 
Morphometric analysis of murine skin wound healing: standardization of experimental 
procedures and impact of an advanced multitissue array technique. Wound Repair Regen. 
2007: 15, 105-12. 
Own contributions: 
I was involved in analyzing the stained paraffin sections and morphometric analysis. 
Moreover I performed the statistical evaluation and most of the graphical illustration of the 
data. 
 
Veit G., Zimina E. P., Franzke C. W., Kutsch S., Siebolts U., Gordon M. K., Bruckner-
Tuderman L. and Koch M. Shedding of collagen XXIII is mediated by furin and depends on 
the plasma membrane microenvironment. J Biol Chem. 2007: 282, 27424-35. 
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Own contributions: 
I performed RT-QPCR for quantification of collagen XXIII, and all subsequent data analysis 
and graphical illustration. 
 
Odenthal M., Siebolts U., Ernestus K., Disse D., Dienes H. P. and Wickenhauser C. 
Immunoglobulin heavy chain gene analysis in bone marrow biopsies and corresponding 
lymph node specimens: dependency on pre-treatment, histological subtype and extension of 
B-cell lymphoma. Int J Mol Med. 2008: 21, 569-76. 
Own contributions: 
I was involved in analyzing the stained paraffin sections and analysis of the 
immunochemistry. Furthermore I analyzed the IgH FR3 PCR and electropherograms and did 
all of the graphical illustration. 
 
Markert E.*, Siebolts U.*, Odenthal M., Kreuzer K. A. and Wickenhauser C. High diagnostic 
value of morphologic examination and molecular analysis of bone marrow biopsies in a case 
of BCR-ABL+ CML with clusters of blasts. Int J Hematol. 2009: 89, 294-7. 
* Both authors contributed equally 
Own contributions: 
I was involved in analyzing the stained paraffin sections and analysis of FISH. Moreover I 
designed the detection assay for BCR-ABL on formalin fixed and paraffin embedded tissue 
and furthermore performed the RT-QPCR with all subsequent data analysis and graphical 
illustration. 
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Markert E.*, Siebolts U.*, Habbig S., Odenthal M., Dienes H. P., Stippel D. L., Hoppe B. and 
Wickenhauser C. Evolution of PTLD following renal transplantation in a child. Pediatr 
Transplant. 2009: 13, 379-83. 
* Both authors contributed equally 
Own contributions: 
I was involved in conception, in analyzing the stained paraffin sections and analysis of the 
immunochemistry. Furthermore I provided the IgH FR3 PCR and electropherograms and did 
most of the graphical illustration. 
 
Utermohlen O., Baschuk N., Abdullah Z., Engelmann A., Siebolts U., Wickenhauser C., 
Stocking C. and Kronke M. Immunologic hurdles of therapeutic stem cell transplantation. 
Biol Chem. 2009: 390, 977-83. 
Own contributions: 
I was involved in analyzing the stained paraffin sections and analysis of the 
immunochemistry. Furthermore I participated in making graphical illustration. 
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